Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 498 articles:
HTML format



Single Articles


    June 2021
  1. OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
    Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.
    PubMed    


    February 2021
  2. WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
    Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Br J Haematol. 2021;192:e112-e115.
    PubMed    


  3. WANG J
    Leukaemia blues - an unusual presentation of leukaemia cutis.
    Br J Haematol. 2021;192:676.
    PubMed    


  4. GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
    Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Br J Haematol. 2021;192:720-728.
    PubMed     Abstract available


  5. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.
    PubMed    


  6. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.
    PubMed    


  7. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.
    PubMed    


  8. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    PubMed     Abstract available


  9. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    PubMed     Abstract available


  10. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    PubMed     Abstract available


  11. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    PubMed     Abstract available


    January 2021
  12. AKINOSOGLOU K, Paliogianni F, Spyridonidis A, Symeonidis A, et al
    SARS-CoV-2 persistence and non-protective immunity in infected haematological patients.
    Br J Haematol. 2021;192:e51-e54.
    PubMed    


  13. BRECCIA M
    Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:237-238.
    PubMed    


  14. ROSS DM, Hughes TP
    Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
    Br J Haematol. 2021;192:24-27.
    PubMed     Abstract available


  15. KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
    Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Br J Haematol. 2021;192:e60-e63.
    PubMed    


  16. FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
    Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Br J Haematol. 2021;192:292-299.
    PubMed     Abstract available


  17. JIN W, Chen L, Liu Y, Chen Q, et al
    A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:e32-e36.
    PubMed    


  18. OTTAVIANO G, Baird S, Bonney D, Connor P, et al
    The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
    Br J Haematol. 2021;192:e42-e44.
    PubMed    


  19. CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
    Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2021;192:333-342.
    PubMed     Abstract available


  20. GALE RP, Saglio G
    Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
    Br J Haematol. 2021;192:22-23.
    PubMed    


  21. MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
    Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
    Br J Haematol. 2021;192:e7-e11.
    PubMed    


  22. MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
    Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
    Br J Haematol. 2021;192:137-145.
    PubMed     Abstract available


  23. FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
    Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
    Br J Haematol. 2021;192:129-136.
    PubMed     Abstract available


  24. RADICH J
    Molecular testing of chronic myeloid leukaemia in low resource areas.
    Br J Haematol. 2021;192:28-32.
    PubMed     Abstract available


  25. DUAN W, Liu X, Jia J, Wang J, et al
    The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Br J Haematol. 2021;192:265-271.
    PubMed     Abstract available


  26. MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
    Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
    Br J Haematol. 2021;192:62-74.
    PubMed     Abstract available


    December 2020
  27. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.
    PubMed    


  28. NELSON ND, McMahon CM, El-Sharkawy Navarro F, Freyer CW, et al
    Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia.
    Br J Haematol. 2020;191:935-938.
    PubMed    


  29. CHEN J, Wang F, Fang J, Nie D, et al
    Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.
    Br J Haematol. 2020;191:e113-e116.
    PubMed    


  30. PARRY-JONES N, Joshi A, Forconi F, Dearden C, et al
    Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).
    Br J Haematol. 2020;191:730-737.
    PubMed    


  31. GANGAT N, Morsia E, Foran JM, Palmer JM, et al
    Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.
    Br J Haematol. 2020;191:e120-e124.
    PubMed    


  32. MOORMAN AV, Schwab C, Winterman E, Hancock J, et al
    Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
    Br J Haematol. 2020;191:844-851.
    PubMed     Abstract available


  33. MERYK A, Kropshofer G, Hutter J, Fritz J, et al
    Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.
    Br J Haematol. 2020;191:816-824.
    PubMed     Abstract available


  34. SIBAI H, Chen R, Liu X, Falcone U, et al
    Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
    Br J Haematol. 2020;191:748-754.
    PubMed     Abstract available


  35. FRISCH A, Rowe JM, Ofran Y
    How we treat older patients with acute myeloid leukaemia.
    Br J Haematol. 2020;191:682-691.
    PubMed     Abstract available


    November 2020
  36. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.
    PubMed    


  37. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    PubMed     Abstract available


  38. MONDELLO P, Zelenetz AD
    Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy.
    Br J Haematol. 2020;191:326-328.
    PubMed    


  39. CHAGALUKA G, Schwalbe EC, Chakumatha E, Carey P, et al
    Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting - the Blantyre experience.
    Br J Haematol. 2020;191:e87-e90.
    PubMed    


  40. CASSADAY RD, Marks DI, DeAngelo DJ, Jabbour EJ, et al
    Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
    Br J Haematol. 2020;191:e77-e81.
    PubMed    


  41. TUEUR G, Lazarian G, Eclache V, Fleury C, et al
    Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
    Br J Haematol. 2020;191:e90-e94.
    PubMed    


  42. MATTSSON A, Sylvan SE, Asklid A, Wiggh J, et al
    Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
    Br J Haematol. 2020;191:426-432.
    PubMed     Abstract available


  43. DERRIEUX C, Gish A, Caulier A, Grardel N, et al
    Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring.
    Br J Haematol. 2020;191:506-509.
    PubMed    


  44. IRANI YD, Hughes A, Clarson J, Kok CH, et al
    Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Br J Haematol. 2020;191:433-441.
    PubMed     Abstract available


    October 2020
  45. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.
    PubMed    


  46. FOX TA, Troy-Barnes E, Kirkwood AA, Chan WY, et al
    Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
    Br J Haematol. 2020;191:194-206.
    PubMed     Abstract available


  47. CLARK RE
    Another set of guidelines for chronic myeloid leukaemia.
    Br J Haematol. 2020;191:147-149.
    PubMed    


  48. GILLEECE MH, Savani BN
    A stitch in time saves nine... MRD-based pre-emptive therapy.
    Br J Haematol. 2020;191:19-20.
    PubMed    


  49. BO A, Raiola AM, Gualandi F, Orengo G, et al
    Unintentional human leukocyte antigen-mismatched haematopoietic cell transplant: clinical course and root cause analysis.
    Br J Haematol. 2020;191:e35-e37.
    PubMed    


  50. MONTORO J, Chorao P, Quintero A, Roca J, et al
    Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation.
    Br J Haematol. 2020;191:12.
    PubMed    


  51. SMITH G, Apperley J, Milojkovic D, Cross NCP, et al
    A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
    Br J Haematol. 2020;191:171-193.
    PubMed    


  52. MCCLURE BJ, Heatley SL, Rehn J, Breen J, et al
    High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse.
    Br J Haematol. 2020;191:301-304.
    PubMed    


  53. RASHIDI A, Kaiser T, Ebadi M, Holtan SG, et al
    Circulating bacterial DNA and neutropenic fever during anti-leukaemia chemotherapy.
    Br J Haematol. 2020;191:e55-e58.
    PubMed    


  54. DONG S, Khedro T, Ward P, Dubeau L, et al
    First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia.
    Br J Haematol. 2020;191:e52-e55.
    PubMed    


  55. KONG D, Qu C, Dai H, Li Z, et al
    CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph(+) mixed phenotype acute leukaemia with minimal residual disease.
    Br J Haematol. 2020;191:e47-e49.
    PubMed    


  56. KHALIFE R, Montroy J, Grigor EJM, Fergusson DA, et al
    Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.
    Br J Haematol. 2020;191:e14-e19.
    PubMed    


  57. PAUL S, Jammal N, Akhave N, Aung PP, et al
    Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia.
    Br J Haematol. 2020;191:e10-e13.
    PubMed    


  58. CERRANO M, Castella B, Lia G, Olivi M, et al
    Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:e28-e32.
    PubMed    


  59. RYLAND GL, Barraclough A, Fong CY, Fleming S, et al
    Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:123-126.
    PubMed    


  60. ZABKIEWICZ J, Lazenby M, Edwards G, Bygrave CA, et al
    Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
    Br J Haematol. 2020;191:231-242.
    PubMed     Abstract available


  61. WANG J, Mou N, Yang Z, Li Q, et al
    Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:212-222.
    PubMed     Abstract available


  62. GANZEL C, Wang XV, Rowe JM, Richards SM, et al
    At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.
    Br J Haematol. 2020;191:37-43.
    PubMed     Abstract available


    September 2020
  63. ORF K, Rogosic S, Dexter D, Ancliff P, et al
    Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
    Br J Haematol. 2020;190:e274-e276.
    PubMed    


  64. SILLA L
    Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.
    Br J Haematol. 2020;190:e322-e323.
    PubMed    


  65. NESR G, Koshy R, Foldes D, Kagdi H, et al
    Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naive chronic lymphocytic leukaemia: a case report.
    Br J Haematol. 2020;190:e326-e328.
    PubMed    


  66. SMOLEJ L
    Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle.
    Br J Haematol. 2020;190:815-816.
    PubMed    


  67. EYRE TA
    Prognostication in Richter syndrome: context is everything.
    Br J Haematol. 2020;190:811-812.
    PubMed    


  68. CORBINGI A, Innocenti I, Tomasso A, Pasquale R, et al
    Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;190:901-908.
    PubMed     Abstract available


  69. SHOUMARIYEH K, Hussung S, Niemoller C, Bleul S, et al
    Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
    Br J Haematol. 2020;190:e339-e343.
    PubMed    


  70. DE PROPRIS MS, Intoppa S, Milani ML, Mariglia P, et al
    ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;190:e346-e349.
    PubMed    


  71. SAITO Y, Makita S, Chinen S, Kito M, et al
    Acute megakaryoblastic leukaemia with t(1;22)(p13.3;q13.1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour.
    Br J Haematol. 2020;190:e329-e332.
    PubMed    


  72. BRECCIA M, Vignetti M, Annibali O, Cottone F, et al
    Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.
    Br J Haematol. 2020;190:e304-e307.
    PubMed    


  73. FOX LC, Tan M, Brown AL, Arts P, et al
    A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.
    Br J Haematol. 2020;190:e297-e301.
    PubMed    


  74. YAMANE T, Kawakami T, Sekiguchi N, Kobayashi J, et al
    High frequency of STAT3 gene mutations in T-cell receptor (TCR)gammadelta-type T-cell large granular lymphocytic leukaemia: implications for molecular diagnostics.
    Br J Haematol. 2020;190:e301-e304.
    PubMed    


  75. HANEKAMP D, Snel AN, Kelder A, Scholten WJ, et al
    Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
    Br J Haematol. 2020;190:891-900.
    PubMed     Abstract available


  76. OFFNER F, Robak T, Janssens A, Govind Babu K, et al
    A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
    Br J Haematol. 2020;190:736-740.
    PubMed     Abstract available


  77. TURKINA A, Wang J, Mathews V, Saydam G, et al
    TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.
    Br J Haematol. 2020;190:869-876.
    PubMed     Abstract available


  78. VARGHESE AM, Sood N, Daniel SM
    Current pricing model for cancer drugs - is it 'Justum Pretium' for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration.
    Br J Haematol. 2020;190:e292-e294.
    PubMed    


  79. EL CHAER F, Ballen KK
    Treatment of acute leukaemia in adult Jehovah's Witnesses.
    Br J Haematol. 2020;190:696-707.
    PubMed     Abstract available


    August 2020
  80. RANGER A, Haji R, Kaczmarski R, Danga A, et al
    Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Br J Haematol. 2020;190:e128-e130.
    PubMed    


  81. PICIOCCHI A, Messina M, Soddu S, La Sala E, et al
    The COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.
    Br J Haematol. 2020;190:e211-e214.
    PubMed    


  82. FARAH N, Burt R, Ibrahim AR, Baker R, et al
    Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
    Br J Haematol. 2020;190:e208-e210.
    PubMed    


  83. CHOPRA J, Hiew HJ, Cumpstey A, Cagampang F, et al
    Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID-19 pneumonia.
    Br J Haematol. 2020;190:e195-e198.
    PubMed    


  84. INNES AJ, Cook LB, Marks S, Bataillard E, et al
    Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
    Br J Haematol. 2020;190:e198-e200.
    PubMed    


  85. WILSON AJ, Troy-Barnes E, Subhan M, Clark F, et al
    Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
    Br J Haematol. 2020;190:e189-e191.
    PubMed    


  86. FARMER I, Okikiolu J, Steel M, Wanniarachchi C, et al
    Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.
    Br J Haematol. 2020;190:e248-e250.
    PubMed    


  87. LEISCH M, Greil R, Pleyer L
    IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
    Br J Haematol. 2020;190:314-317.
    PubMed    


  88. ANDREWS C, Maze D, Murphy T, Sibai H, et al
    Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
    Br J Haematol. 2020;190:467-470.
    PubMed    


  89. ZHU J, Raimbault A, Sourdeau E, Maillon A, et al
    Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry.
    Br J Haematol. 2020;190:e255-e258.
    PubMed    


  90. GLAVEY SV, Flanagan L, Bleach R, Kelly C, et al
    Secondary plasma cell leukaemia treated with single agent venetoclax.
    Br J Haematol. 2020;190:e242-e245.
    PubMed    


  91. CHOWDHURY A, Loaiza S, Yebra-Fernandez E, Nadal-Melsio E, et al
    An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets.
    Br J Haematol. 2020;190:e236-e239.
    PubMed    


  92. FIEDLER W, Chromik J, Amberg S, Kebenko M, et al
    A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
    Br J Haematol. 2020;190:e169-e173.
    PubMed    


  93. NIE D, Zhang J, Xiong M, Wang F, et al
    Complete remission of refractory juvenile acute myeloid leukaemia with RUNX1-PRDM16 in Bloom syndrome after haematopoietic stem cell transplantation.
    Br J Haematol. 2020;190:e166-e169.
    PubMed    


  94. PETERLIN P, Cluzeau T, Jullien M, Ngo Nloga AM, et al
    Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
    Br J Haematol. 2020;190:461-464.
    PubMed    


  95. LOKE J, Lowe DM, Miller LJ, Morton S, et al
    Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?
    Br J Haematol. 2020;190:311-313.
    PubMed    


  96. LEBLANC FR, Pearson JM, Tan SF, Cheon H, et al
    Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
    Br J Haematol. 2020;190:405-417.
    PubMed     Abstract available


  97. WANG J, Lu R, Wu Y, Jia J, et al
    Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Br J Haematol. 2020;190:533-544.
    PubMed     Abstract available


  98. WILHELMSON AS, Porse BT
    CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
    Br J Haematol. 2020;190:495-507.
    PubMed     Abstract available


  99. SAGLIO G, Gale RP
    Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
    Br J Haematol. 2020;190:318-327.
    PubMed     Abstract available


  100. HERUDKOVA Z, Culen M, Folta A, Jeziskova I, et al
    Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
    Br J Haematol. 2020;190:562-572.
    PubMed     Abstract available


    July 2020
  101. GESTRICH CK, Sadri N, Sinno MG, Pateva I, et al
    Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Br J Haematol. 2020 Jul 29. doi: 10.1111/bjh.17000.
    PubMed    


  102. BLENNERHASSETT R, Kwan J, Coyle L, Wong K, et al
    Adult B- and T-lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes-a short report from two Sydney centres.
    Br J Haematol. 2020 Jul 28. doi: 10.1111/bjh.16998.
    PubMed    


  103. BARNEA SLONIM L, Ma S, Behdad A, Chen Q, et al
    Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    Br J Haematol. 2020 Jul 17. doi: 10.1111/bjh.16948.
    PubMed    


  104. YANG Y, Juskevicius R
    T-lymphoblastic leukaemia/lymphoma with rosettes and gland-like structures.
    Br J Haematol. 2020 Jul 7. doi: 10.1111/bjh.16929.
    PubMed    


  105. FOA R, Bonifacio M, Chiaretti S, Curti A, et al
    Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study.
    Br J Haematol. 2020;190:e3-e5.
    PubMed    


  106. DAY JW, Fox TA, Halsey R, Carpenter B, et al
    Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
    Br J Haematol. 2020;190:e80-e83.
    PubMed    


  107. KRUG U, Berdel WE
    Smoking and AML - another piece in the puzzle.
    Br J Haematol. 2020;190:143.
    PubMed    


  108. MALAGOLA M, Bernardi S, Polverelli N, Russo D, et al
    Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?
    Br J Haematol. 2020;190:135-136.
    PubMed    


  109. BARON F, Savani BN
    Graft-versus-host-disease does not help acute lymphoblastic leukaemia patients with measurable residual disease.
    Br J Haematol. 2020;190:22-23.
    PubMed    


  110. ARMAND P, Murawski N, Molin D, Zain J, et al
    Pembrolizumab in relapsed or refractory Richter syndrome.
    Br J Haematol. 2020;190:e117-e120.
    PubMed    


  111. CALVO C, Cabannes-Hamy A, Adjaoud D, Bruno B, et al
    Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;190:e53-e56.
    PubMed    


  112. KAUR U, Gambhir IS, Khare VR, Singh A, et al
    Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
    Br J Haematol. 2020;190:e51-e53.
    PubMed    


  113. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
    The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study.
    Br J Haematol. 2020;190:236-243.
    PubMed     Abstract available


  114. REA B, Bailey NG
    Acute myeloid leukaemia with t(8;16)(p11.2;p13.3) and erythrophagocytosis.
    Br J Haematol. 2020;190:133.
    PubMed    


  115. JUUL-DAM KL, Ommen HB, Nyvold CG, Walter C, et al
    Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
    Br J Haematol. 2020;190:198-208.
    PubMed     Abstract available


  116. BENEFORTI L, Dander E, Bresolin S, Bueno C, et al
    Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche.
    Br J Haematol. 2020;190:262-273.
    PubMed     Abstract available


  117. ZHOU YL, Wu LX, Peter Gale R, Wang ZL, et al
    Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
    Br J Haematol. 2020;190:274-283.
    PubMed     Abstract available


  118. ZHANG JM, Xu Y, Gale RP, Wu LX, et al
    DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;190:67-78.
    PubMed     Abstract available


    June 2020
  119. FAVRESSE J, Eucher C, Elsen M, Graux C, et al
    Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia.
    Br J Haematol. 2020 Jun 17. doi: 10.1111/bjh.16954.
    PubMed     Abstract available


  120. YANG LH, Zhao Y, Maule J, Rapisardo S, et al
    T-lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classificat
    Br J Haematol. 2020 Jun 11. doi: 10.1111/bjh.16886.
    PubMed    


  121. ABRISQUETA P, Delgado J, Alcoceba M, Oliveira AC, et al
    Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16748.
    PubMed     Abstract available


  122. LARSSON K, Mattsson M, Ebrahim F, Glimelius I, et al
    High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16859.
    PubMed    


  123. BATALLER A, Onate G, Diaz-Beya M, Guijarro F, et al
    Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
    Br J Haematol. 2020 Jun 8. doi: 10.1111/bjh.16857.
    PubMed     Abstract available


  124. WILLAN J, King AJ, Djebbari F, Turner GDH, et al
    Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID-19 pandemic.
    Br J Haematol. 2020;189:e224-e227.
    PubMed    


  125. SIENI E, Pegoraro F, Casini T, Tondo A, et al
    Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
    Br J Haematol. 2020;189:e222-e224.
    PubMed    


  126. LANGERAK AW, Davi F, Stamatopoulos K
    Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?
    Br J Haematol. 2020;189:809-810.
    PubMed    


  127. STAHL M, Tallman MS
    Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission.
    Br J Haematol. 2020;189:806-808.
    PubMed    


  128. RAEDLER J, Heyde S, Kolokythas M, Eichinger A, et al
    Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.
    Br J Haematol. 2020;189:e251-e254.
    PubMed    


  129. DHAMI SPS, Tirincsi A, Baev D, Krawczyk J, et al
    Theranostic drug test incorporating the bone-marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy.
    Br J Haematol. 2020;189:e254-e258.
    PubMed    


  130. LI XY, Qian JJ, Yang M, Zhang Y, et al
    An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e231-e234.
    PubMed    


  131. DE FIGUEIREDO AF, Land MGP, Ferreira GM, Mencalha A, et al
    Clinical and biological correlates of the expression of select Polycomb complex genes in Brazilian children with acute promyelocytic leukaemia.
    Br J Haematol. 2020;189:e245-e248.
    PubMed    


  132. WU X, Zhang J, Chen Q, Zhou L, et al
    Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
    Br J Haematol. 2020;189:e200-e204.
    PubMed    


  133. GONG Z, Zhou T, Liu H, Tang G, et al
    Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.
    Br J Haematol. 2020;189:e207-e211.
    PubMed    


  134. ZHANG J, Wang Y, Li SQ, Fang L, et al
    Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
    Br J Haematol. 2020;189:1141-1150.
    PubMed     Abstract available


  135. LADIKOU EE, Chevassut T, Pepper CJ, Pepper AG, et al
    Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Br J Haematol. 2020;189:815-825.
    PubMed     Abstract available


  136. RAPONI S, Ilari C, Della Starza I, Cappelli LV, et al
    Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Br J Haematol. 2020;189:853-859.
    PubMed     Abstract available


  137. DIAZ-BEYA M, Labopin M, Maertens J, Alijurf M, et al
    Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
    Br J Haematol. 2020;189:920-925.
    PubMed     Abstract available


  138. AL-ALI HK, Griesshammer M, Foltz L, Palumbo GA, et al
    Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Br J Haematol. 2020;189:888-903.
    PubMed     Abstract available


  139. PATEL BJ, Barot SV, Kuzmanovic T, Kerr C, et al
    Distinctive and common features of moderate aplastic anaemia.
    Br J Haematol. 2020;189:967-975.
    PubMed     Abstract available


    May 2020
  140. THIBAUD S, Tremblay D, Bhalla S, Zimmerman B, et al
    Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID-19.
    Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16863.
    PubMed     Abstract available


  141. WU Y, Lin H, Xie Q, Chen Q, et al
    COVID-19 in a patient with pre-existing acute lymphoblastic leukemia.
    Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16799.
    PubMed     Abstract available


  142. BALDACINI M, Pop R, Sattler L, Mauvieux L, et al
    Concomitant hemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukemia.
    Br J Haematol. 2020 May 5. doi: 10.1111/bjh.16768.
    PubMed     Abstract available


  143. ANTELO G, Mangaonkar AA, Coltro G, Buradkar A, et al
    Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
    Br J Haematol. 2020;189:e104-e108.
    PubMed    


  144. GU X, Saunthararajah Y
    Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation.
    Br J Haematol. 2020;189:578-581.
    PubMed    


  145. GRIBBEN JG
    Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?
    Br J Haematol. 2020;189:603-604.
    PubMed    


  146. RAYMOND LM, Funk T, Braziel RM, Fan G, et al
    Mast cell sarcoma with concurrent mast cell leukaemia.
    Br J Haematol. 2020;189:e160-e164.
    PubMed    


  147. ADELAIDE J, Cervera N, Guille A, Murati A, et al
    Gains of EPOR and ERG genes in adult erythroleukaemia.
    Br J Haematol. 2020;189:e174-e177.
    PubMed    


  148. INABA H, Cao X, Chang JY, Karol SE, et al
    Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e177-e181.
    PubMed    


  149. GIUSTI GNN, Jotta PY, Lopes CO, Ganazza MA, et al
    Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e150-e154.
    PubMed    


  150. ROBINSON SE, Harrison CN
    How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
    Br J Haematol. 2020;189:625-634.
    PubMed     Abstract available


  151. PRIETO-CONDE MI, Jimenez C, Garcia-Alvarez M, Ramos F, et al
    Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.
    Br J Haematol. 2020;189:718-730.
    PubMed     Abstract available


  152. ONECHA E, Ruiz-Heredia Y, Martinez-Cuadron D, Barragan E, et al
    Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
    Br J Haematol. 2020;189:672-683.
    PubMed     Abstract available


  153. UDEN T, Bertaina A, Abrahamsson J, Ansari M, et al
    Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
    Br J Haematol. 2020;189:745-750.
    PubMed     Abstract available


  154. MIKLOS U, Strugov V, Lewerin C, Grosicki S, et al
    Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
    Br J Haematol. 2020;189:689-693.
    PubMed     Abstract available


  155. CICIARELLO M, Curti A
    Good news for acute myeloid leukaemia patients from the stroll niche?
    Br J Haematol. 2020;189:597-599.
    PubMed    


  156. CHEN X, Chen H
    BCR-ABL1-positive acute myeloid leukaemia relapsing as acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:591.
    PubMed    


  157. JIANG Y, Li Y, Cheng J, Ma J, et al
    Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells.
    Br J Haematol. 2020;189:694-706.
    PubMed     Abstract available


  158. ZHAO Y, Maule J, McCracken J, Li Y, et al
    Acute myeloid leukaemia with maturation demonstrates persistent disease with prominent megakaryoblastic differentiation 16 days following induction chemotherapy: an intra-myeloid lineage switch mediated by chemotherapy-induced clonal selection.
    Br J Haematol. 2020;189:e64-e67.
    PubMed    


  159. DULUCQ S, Astrugue C, Etienne G, Mahon FX, et al
    Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
    Br J Haematol. 2020;189:452-468.
    PubMed     Abstract available


  160. JORDAENS S, Cooksey L, Bonney S, Orchard L, et al
    Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:500-512.
    PubMed     Abstract available


  161. DELVECCHIO VS, Sana I, Mantione ME, Vilia MG, et al
    Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
    Br J Haematol. 2020;189:475-488.
    PubMed     Abstract available


  162. MARAJ A, MacEneaney O, Doyle B, Quinn J, et al
    Lysozyme-induced nephropathy: a rare manifestation of chronic myelomonocytic leukaemia.
    Br J Haematol. 2020;189:393.
    PubMed    


  163. LINCH DC, Hills RK, Burnett AK, Gale RE, et al
    The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
    Br J Haematol. 2020;189:e81-e86.
    PubMed    


  164. MANOUSOPOULOU A, Wang LD
    ALL the comforts of homing: lymphoblasts find cerebrospinal fluid inhospitable without meningeal cell contact.
    Br J Haematol. 2020;189:395-397.
    PubMed    


  165. VAN DER STRATEN L, Levin MD, Visser O, Posthuma EFM, et al
    Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.
    Br J Haematol. 2020;189:574-577.
    PubMed    


  166. BASILE P, Jonart LM, Ebadi M, Johnson K, et al
    The meninges enhance leukaemia survival in cerebral spinal fluid.
    Br J Haematol. 2020;189:513-517.
    PubMed     Abstract available


  167. KLOOS R, van der Sluis IM, Mastrobattista E, Hennink W, et al
    Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
    Br J Haematol. 2020;189:442-451.
    PubMed     Abstract available


    April 2020
  168. FUSTER JL, Molinos-Quintana A, Fuentes C, Fernandez JM, et al
    Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
    Br J Haematol. 2020 Apr 21. doi: 10.1111/bjh.16647.
    PubMed     Abstract available


  169. COGLE CR, Collins B, Turner D, Pettiford LC, et al
    Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
    Br J Haematol. 2020 Apr 1. doi: 10.1111/bjh.16629.
    PubMed    


  170. DHOLARIA B, Savani BN
    Allogeneic haematopoietic cell transplantation after CAR T-cell therapy: safe, effective and contentious.
    Br J Haematol. 2020;189:21-23.
    PubMed    


  171. BERTOLI S, Rieu JB, Recher C, Vergez F, et al
    Large granular lymphocytosis during quizartinib therapy.
    Br J Haematol. 2020;189:7.
    PubMed    


  172. EBADI M, Beckman AK, Yohe SL, Rashidi A, et al
    It's all in the film.
    Br J Haematol. 2020;189:8.
    PubMed    


  173. OSTERROOS A, Eriksson A, Antunovic P, Cammenga J, et al
    Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged >/= 60 years.
    Br J Haematol. 2020;189:e13-e16.
    PubMed    


  174. GODWIN CD, Bates OM, Garling EE, Beddoe ME, et al
    The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
    Br J Haematol. 2020;189:e9-e13.
    PubMed    


  175. XU X, Zeng Z, Huo L, Liu H, et al
    High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype.
    Br J Haematol. 2020;189:e23-e27.
    PubMed    


  176. ZHANG Y, Chen H, Song Y, Tan X, et al
    Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
    Br J Haematol. 2020;189:146-152.
    PubMed     Abstract available


  177. ROESSNER PM, Hanna BS, Ozturk S, Schulz R, et al
    TBET-expressing Th1 CD4(+) T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in Emicro-TCL1 mice.
    Br J Haematol. 2020;189:133-145.
    PubMed     Abstract available


  178. WANG Y, Liu QF, Wu DP, Xu LP, et al
    Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients.
    Br J Haematol. 2020;189:153-161.
    PubMed     Abstract available


  179. YANG RY, Yang CX, Lang XP, Duan LJ, et al
    Identification of a novel RUNX1-TACC1 fusion transcript in acute myeloid leukaemia.
    Br J Haematol. 2020;189:e52-e56.
    PubMed    


  180. DO YR, Kwak JY, Kim JA, Kim HJ, et al
    Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
    Br J Haematol. 2020;189:303-312.
    PubMed     Abstract available


  181. ROSSOFF J, Huynh V, Rau RE, Macy ME, et al
    Experience with ponatinib in paediatric patients with leukaemia.
    Br J Haematol. 2020;189:363-368.
    PubMed     Abstract available


  182. AWADA H, Mahfouz RZ, Durrani J, Kishtagari A, et al
    Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation.
    Br J Haematol. 2020;189:318-322.
    PubMed     Abstract available


  183. FRAZZI R, Bizzarri V, Albertazzi L, Cusenza VY, et al
    Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;189:e49-e52.
    PubMed    


  184. BANKAR A, Korula A, Kulkarni UP, Devasia AJ, et al
    Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
    Br J Haematol. 2020;189:269-278.
    PubMed     Abstract available


  185. PIETTE C, Suciu S, Bertrand Y, Uyttebroeck A, et al
    Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study.
    Br J Haematol. 2020;189:351-362.
    PubMed     Abstract available


    March 2020
  186. AKAHOSHI Y, Igarashi A, Fukuda T, Uchida N, et al
    Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16540.
    PubMed     Abstract available


  187. PIANIGIANI G, Betti C, Brunetti L
    Response to: "Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukemia is obscured by paraformaldehyde fixation".
    Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16544.
    PubMed    


  188. TOUW IP, Sanders MA
    Mutant allelic burden in acute myeloid leukaemia: Why bother?
    Br J Haematol. 2020;188:817-818.
    PubMed    


  189. RICHARDSON AI, Skikne BS, Woodroof J
    Chronic myeloid leukaemia, BCR-ABL1-positive, in accelerated phase with marked eosinophilia with eosinophil atypia.
    Br J Haematol. 2020;188:599.
    PubMed    


  190. RADIA DH, Green A, Oni C, Moonim M, et al
    The clinical and pathological panoply of systemic mastocytosis.
    Br J Haematol. 2020;188:623-640.
    PubMed     Abstract available


  191. XUE YJ, Suo P, Huang XJ, Lu AD, et al
    Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic le
    Br J Haematol. 2020;188:757-767.
    PubMed     Abstract available


  192. PALOMO L, Ibanez M, Abaigar M, Vazquez I, et al
    Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
    Br J Haematol. 2020;188:605-622.
    PubMed     Abstract available


  193. KNOFLER R, Lange BS, Paul F, Tiebel O, et al
    Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children.
    Br J Haematol. 2020;188:701-706.
    PubMed     Abstract available


  194. KIM YA, Ju HY, Park HJ, Lee NY, et al
    Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients.
    Br J Haematol. 2020;188:740-744.
    PubMed     Abstract available


  195. CUCCHI DGJ, Bachas C, Klein K, Huttenhuis S, et al
    TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.
    Br J Haematol. 2020;188:736-739.
    PubMed     Abstract available


  196. ZHAO C, Jia B, Wang M, Schell TD, et al
    Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.
    Br J Haematol. 2020;188:674-684.
    PubMed     Abstract available


  197. CHIN-YEE B, Sadikovic B, Chin-Yee IH
    Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:652-660.
    PubMed     Abstract available


  198. GIONA F, Malaspina F, Putti MC, Ladogana S, et al
    Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
    Br J Haematol. 2020;188:e101-e105.
    PubMed    


  199. GAUR V, Chaudhary S, Tyagi A, Agarwal S, et al
    Dysregulation of miRNA expression and their prognostic significance in paediatric cytogenetically normal acute myeloid leukaemia.
    Br J Haematol. 2020;188:e90-e94.
    PubMed    


  200. VAN DER STRATEN L, Levin MD, Visser O, Blijlevens NMA, et al
    The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    Br J Haematol. 2020;188:e109-e112.
    PubMed    


  201. GRIBBEN JG
    Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:844-851.
    PubMed     Abstract available


  202. ZHOU C, Zhuang Y, Lin X, Michelson AD, et al
    Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis.
    Br J Haematol. 2020;188:945-961.
    PubMed     Abstract available


  203. HOLTZMAN NG, El Chaer F, Baer MR, Ali O, et al
    Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.
    Br J Haematol. 2020;188:881-887.
    PubMed     Abstract available


  204. ELSTON L, Fegan C, Hills R, Hashimdeen SS, et al
    Increased frequency of CD4(+) PD-1(+) HLA-DR(+) T cells is associated with disease progression in CLL.
    Br J Haematol. 2020;188:872-880.
    PubMed     Abstract available


  205. EYRE TA, Roeker LE, Fox CP, Gohill SH, et al
    The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:918-923.
    PubMed     Abstract available


  206. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
    Br J Haematol. 2020;188:852-859.
    PubMed     Abstract available


    February 2020
  207. DALAL NH, Dores GM, Curtis RE, Linet MS, et al
    Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia, 2000-2016.
    Br J Haematol. 2020 Feb 23. doi: 10.1111/bjh.16492.
    PubMed     Abstract available


  208. MONDELAERS V, Ferster A, Uyttebroeck A, Brichard B, et al
    Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Br J Haematol. 2020 Feb 14. doi: 10.1111/bjh.16495.
    PubMed     Abstract available


  209. ETIENNE G, Dulucq S, Faberes C, Bijou F, et al
    A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study.
    Br J Haematol. 2020 Feb 10. doi: 10.1111/bjh.16511.
    PubMed    


  210. ROMZOVA M, Smitalova D, Tom N, Jurcek T, et al
    Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
    Br J Haematol. 2020 Feb 9. doi: 10.1111/bjh.16382.
    PubMed     Abstract available


  211. MATSUO T, Ooi J, Tashiro H, Saito S, et al
    A major break of cord blood bag.
    Br J Haematol. 2020;188:e42-e43.
    PubMed    


  212. HOCKINGS C, Gohil S, Dowse R, Hoade Y, et al
    In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation.
    Br J Haematol. 2020;188:e53-e57.
    PubMed    


  213. NILSSON MS, Hallner A, Brune M, Nilsson S, et al
    Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
    Br J Haematol. 2020;188:e49-e53.
    PubMed    


  214. GURNEY M, Krawczyk J, Paz Nunez YE
    Megakaryocyte emperipolesis in B-lymphoblastic leukaemia.
    Br J Haematol. 2020;188:348.
    PubMed    


  215. CAPITANO M, Capo-Chichi JM, Minden MD, Chang H, et al
    Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile.
    Br J Haematol. 2020;188:e60-e63.
    PubMed    


  216. BROWN P, Zugmaier G, Gore L, Tuglus CA, et al
    Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL.
    Br J Haematol. 2020;188:e36-e39.
    PubMed    


  217. DA COSTA VEF, de Oliveira RD, Traina F, Chahud F, et al
    Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia.
    Br J Haematol. 2020;188:e21-e23.
    PubMed    


  218. SHAHSWAR R, Beutel G, Klement P, Rehberg A, et al
    FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
    Br J Haematol. 2020;188:e11-e15.
    PubMed    


  219. BARON F, Labopin M, Savani BN, Beohou E, et al
    Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.
    Br J Haematol. 2020;188:428-437.
    PubMed     Abstract available


  220. HARA Y, Shiba N, Yamato G, Ohki K, et al
    Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.
    Br J Haematol. 2020;188:528-539.
    PubMed     Abstract available


  221. HANSEN MC, Haferlach T, Nyvold CG
    A decade with whole exome sequencing in haematology.
    Br J Haematol. 2020;188:367-382.
    PubMed     Abstract available


    January 2020

  222. The Management of Acute Leukaemia in Adults.
    Br J Haematol. 2020;188:10-28.
    PubMed    


  223. DEROLF A, Juliusson G, Benson L, Floisand Y, et al
    Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor.
    Br J Haematol. 2020;188:187-191.
    PubMed    


  224. OLIAI C, Schiller G
    How to address second and therapy-related acute myelogenous leukaemia.
    Br J Haematol. 2020;188:116-128.
    PubMed     Abstract available


  225. CHARROT S, Armes H, Rio-Machin A, Fitzgibbon J, et al
    AML through the prism of molecular genetics.
    Br J Haematol. 2020;188:49-62.
    PubMed     Abstract available


  226. HILLS RK
    Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
    Br J Haematol. 2020;188:29-35.
    PubMed     Abstract available


  227. PAUL S, Rausch CR, Jabbour EJ
    The face of remission induction.
    Br J Haematol. 2020;188:101-115.
    PubMed     Abstract available


  228. BURNETT AK, Hills RK, Russell N
    Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
    Br J Haematol. 2020;188:86-100.
    PubMed    


  229. HOKLAND P
    AML - a signature disease in haematology.
    Br J Haematol. 2020;188:7.
    PubMed    


  230. LOKE J, Malladi R, Moss P, Craddock C, et al
    The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.
    Br J Haematol. 2020;188:129-146.
    PubMed     Abstract available


  231. MO X, Chen H
    Acute promyelocytic leukaemia with myeloperoxidase-negative rectangular inclusions.
    Br J Haematol. 2020;188:8.
    PubMed    


  232. HAFERLACH T, Schmidts I
    The power and potential of integrated diagnostics in acute myeloid leukaemia.
    Br J Haematol. 2020;188:36-48.
    PubMed     Abstract available


  233. GARCIA SPEZZA E, Brethon B, Petit A, Mazingue F, et al
    Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
    Br J Haematol. 2020;188:170-173.
    PubMed    


  234. GHOSH A, Barba P, Perales MA
    Checkpoint inhibitors in AML: are we there yet?
    Br J Haematol. 2020;188:159-167.
    PubMed     Abstract available


  235. JONES L, McCarthy P, Bond J
    Epigenetics of paediatric acute myeloid leukaemia.
    Br J Haematol. 2020;188:63-76.
    PubMed     Abstract available


  236. GHANNAM J, Dillon LW, Hourigan CS
    Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
    Br J Haematol. 2020;188:77-85.
    PubMed     Abstract available


  237. WANG T, Wang Z, Zhang L, Wen L, et al
    Identification of a novel TFG-FGFR1 fusion gene in an acute myeloid leukaemia patient with t(3;8)(q12;p11).
    Br J Haematol. 2020;188:177-181.
    PubMed    


  238. BARRETT AJ
    Acute myeloid leukaemia and the immune system: implications for immunotherapy.
    Br J Haematol. 2020;188:147-158.
    PubMed     Abstract available


  239. PIANIGIANI G, Betti C, Bigerna B, Rossi R, et al
    PU.1 subcellular localization in acute myeloid leukaemia with mutated NPM1.
    Br J Haematol. 2020;188:184-187.
    PubMed    


  240. JIANG G, Atenafu EG, Capo-Chichi JM, Minden MD, et al
    Prognostic relevance of CD123 expression in adult AML with normal karyotype.
    Br J Haematol. 2020;188:181-184.
    PubMed    


  241. ESPARZA S, Muluneh B, Galeotti J, Matson M, et al
    Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia.
    Br J Haematol. 2020;188:173-177.
    PubMed    


  242. YIN J, Zhu S, Luo Y, Lin Z, et al
    Acute myeloid leukaemia with Auer rods within pseudo-Chediak-Higashi granules.
    Br J Haematol. 2020;188:9.
    PubMed    


  243. KATAGIRI S, Gotoh A, Ohyashiki K
    Very late relapse with rapid BCR-ABL1 elevation after more than seven years of treatment-free remission with undetectable molecular residual disease in chronic myeloid leukaemia.
    Br J Haematol. 2020;188:332-334.
    PubMed    


  244. RAFEI H, Kantarjian HM, Jabbour EJ
    Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
    Br J Haematol. 2020;188:207-223.
    PubMed     Abstract available


    December 2019
  245. ELITZUR S, Arad-Cohen N, Barg A, Litichever N, et al
    Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia.
    Br J Haematol. 2019 Dec 29. doi: 10.1111/bjh.16329.
    PubMed     Abstract available


  246. HUANG H, Qin T, Xu Z, Shi Z, et al
    Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia.
    Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16326.
    PubMed    


    November 2019
  247. ROSADAS C, Puccioni-Sohler M, Oliveira ACP, Casseb J, et al
    Adult T-cell leukaemia/lymphoma in Brazil: A rare disease or rarely diagnosed?
    Br J Haematol. 2019 Nov 19. doi: 10.1111/bjh.16318.
    PubMed    


    October 2019
  248. NYLAND SB, Feith DJ, Poss M, Olson TL, et al
    Retroviral sero-reactivity in LGL leukaemia patients and family members.
    Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16223.
    PubMed     Abstract available


    July 2019
  249. FERRETTI A, Baldacci E, Miulli E, Canichella M, et al
    Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16114.
    PubMed    


  250. DOMINGUEZ-PINILLA N, Martinez-Zamorano E, Campos-Martin Y, Algara Plana P, et al
    Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia.
    Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089.
    PubMed    


    June 2019
  251. SAKAMOTO K, Shiba N, Deguchi T, Kiyokawa N, et al
    Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16080.
    PubMed     Abstract available


    May 2019
  252. KHOGEER H, Rahman H, Jain N, Angelova EA, et al
    Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15960.
    PubMed     Abstract available


  253. TOYODA K, Tsukasaki K, Machida R, Kadota T, et al
    Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
    Br J Haematol. 2019 May 16. doi: 10.1111/bjh.15950.
    PubMed     Abstract available


    April 2019
  254. THURGOOD LA, Dwyer ES, Lower KM, Chataway TK, et al
    Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis.
    Br J Haematol. 2019;185:65-78.
    PubMed     Abstract available


  255. ZHANG J, Li M, He Y
    Acute promyelocytic leukaemia with increased basophils.
    Br J Haematol. 2019;185:7.
    PubMed    


  256. VISENTIN A, Imbergamo S, Scomazzon E, Pravato S, et al
    BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
    Br J Haematol. 2019;185:193-197.
    PubMed    


  257. HOKLAND P, Hansen MC
    Acute myeloid/T-lymphoblastic leukaemia (ATML) - a disease entity to look out for.
    Br J Haematol. 2019;185:178.
    PubMed    


  258. MILANI G, Matthijssens F, Van Loocke W, Durinck K, et al
    Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.
    Br J Haematol. 2019;185:169-174.
    PubMed    


  259. MORENO C, Delgado J, Byrd JC, Zvagelsky WL, et al
    Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.
    Br J Haematol. 2019;185:148-150.
    PubMed    


  260. CABEZAS M, Camos M, Rives S, Garcia-Orad A, et al
    Impact of polymorphisms in apoptosis-related genes on the outcome of childhood acute lymphoblastic leukaemia.
    Br J Haematol. 2019;185:159-162.
    PubMed    


  261. NAKASONE H, Tabuchi K, Uchida N, Ohno Y, et al
    Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells?
    Br J Haematol. 2019;185:166-169.
    PubMed    


  262. RAPONI S, Del Giudice I, Ilari C, Cafforio L, et al
    Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
    Br J Haematol. 2019;185:156-159.
    PubMed    


    March 2019
  263. BILL M, Aggerholm A, Kjeldsen E, Roug AS, et al
    Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.
    Br J Haematol. 2019;184:769-781.
    PubMed     Abstract available


  264. SCHMID C, Labopin M, Schaap N, Veelken H, et al
    Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.
    Br J Haematol. 2019;184:782-787.
    PubMed     Abstract available


  265. TANG FF, Mo XD, Wang Y, Yan CH, et al
    Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course.
    Br J Haematol. 2019;184:788-796.
    PubMed     Abstract available


  266. KABBAGE S, Cupaiolo R, Rozen L, Demulder A, et al
    Auer rods in neutrophils in bone marrow and peripheral blood in mixed phenotype acute leukaemia in a child.
    Br J Haematol. 2019;184:708.
    PubMed    


  267. CHENG Y, Chen Y, Yan C, Wang Y, et al
    Comments on the article: 'Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoiet
    Br J Haematol. 2019;184:882-883.
    PubMed    


  268. PAN T, Qi J, Liu Y, Wu D, et al
    Comments on the article 'Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoieti
    Br J Haematol. 2019;184:881-882.
    PubMed    


  269. CHEN Y, Peubez C, Jayne S, Kocsis-Fodor G, et al
    Differential activation of pro-survival pathways in response to CD40LG/IL4 stimulation in chronic lymphocytic leukaemia cells.
    Br J Haematol. 2019;184:867-869.
    PubMed    


  270. DING LW, Tan KT, Sun QY, Lao ZT, et al
    Clonality and clonal evolution analysis of paediatric ALL based on B-cell receptor/T-cell receptor rearrangement.
    Br J Haematol. 2019;184:829-833.
    PubMed    


  271. SCHETELIG J, Link CS, Stuhler G, Wagner EM, et al
    Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.
    Br J Haematol. 2019;184:833-836.
    PubMed    


  272. ZUGMAIER G
    Aneuploidy in childhood B cell acute lymphoblastic leukaemia - also a relevant prognostic factor in relapsed disease?
    Br J Haematol. 2019;184:895-896.
    PubMed    


  273. NOETZLI J, Voruz S, Wunder D, Primi MP, et al
    Ten-year single-centre experience in fertility preservation of 459 patients suffering from acute leukaemia.
    Br J Haematol. 2019;184:969-973.
    PubMed     Abstract available


  274. ZHANG J, Li M, He Y
    Granular B-lineage acute lymphoblastic leukaemia mimicking acute myeloid leukaemia.
    Br J Haematol. 2019;184:894.
    PubMed    


  275. OTTMANN OG, Muller-Tidow C, Kramer A, Schlenk RF, et al
    Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
    Br J Haematol. 2019;184:1018-1021.
    PubMed    


  276. IFVERSEN M, Turkiewicz D, Marquart HV, Winiarski J, et al
    Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
    Br J Haematol. 2019;184:982-993.
    PubMed     Abstract available


  277. BARZILAI-BIRENBOIM S, Arad-Cohen N, Nirel R, Avrahami G, et al
    Thrombophilia screening and thromboprophylaxis may benefit specific ethnic subgroups with paediatric acute lymphoblastic leukaemia.
    Br J Haematol. 2019;184:994-998.
    PubMed     Abstract available


  278. IMPROGO MR, Tesar B, Klitgaard JL, Magori-Cohen R, et al
    MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.
    Br J Haematol. 2019;184:925-936.
    PubMed     Abstract available


  279. PIREDDA ML, Gaur G, Catalano G, Divona M, et al
    PML/RARA inhibits expression of HSP90 and its target AKT.
    Br J Haematol. 2019;184:937-948.
    PubMed     Abstract available


  280. BERGER G, van den Berg E, Smetsers S, Leegte BK, et al
    Fanconi anaemia presenting as acute myeloid leukaemia and myelodysplastic syndrome in adulthood: a family report on co-occurring FANCC and CHEK2 mutations.
    Br J Haematol. 2019;184:1071-1073.
    PubMed    


  281. BOMBEN R, Roisman A, D'Agaro T, Castellano G, et al
    Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2-202 has prognostic value in Chronic Lymphocytic Leukaemia.
    Br J Haematol. 2019;184:1045-1050.
    PubMed    


  282. AGRAWAL AK, Aguilar A, Feusner J
    Unifying the diagnosis of isolated central nervous system relapse in acute lymphoblastic leukaemia based on minimal residual disease testing.
    Br J Haematol. 2019;184:1026-1027.
    PubMed    


    February 2019
  283. KHASHAB T, Hagemeister F, Romaguera JE, Fanale MA, et al
    Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 28. doi: 10.1111/bjh.15814.
    PubMed     Abstract available


  284. BURKHARDT B, Hermiston ML
    Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
    Br J Haematol. 2019 Feb 27. doi: 10.1111/bjh.15793.
    PubMed     Abstract available


  285. MIYAMURA T, Moritake H, Nakayama H, Tanaka S, et al
    Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15799.
    PubMed     Abstract available


  286. O'REILLY MA, Govender D, Kirkwood AA, Vora A, et al
    The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
    Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15798.
    PubMed    


  287. MASETTI R, Bertuccio SN, Pession A, Locatelli F, et al
    CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity.
    Br J Haematol. 2019;184:337-347.
    PubMed     Abstract available


  288. CHEN D, Camponeschi A, Wu Q, Gerasimcik N, et al
    CD99 expression is strongly associated with clinical outcome in children with B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2019;184:418-423.
    PubMed     Abstract available


  289. HOJFELDT SG, Wolthers BO, Tulstrup M, Abrahamsson J, et al
    Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
    Br J Haematol. 2019;184:405-417.
    PubMed     Abstract available


  290. TIAN C, Yu Y, Zhang Y
    Waldenstrom macroglobulinaemia terminating in acute lymphoblastic leukaemia after treatment with fludarabine.
    Br J Haematol. 2019;184:322.
    PubMed    


  291. GUARINI A, Peragine N, Messina M, Marinelli M, et al
    Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
    Br J Haematol. 2019;184:392-396.
    PubMed     Abstract available


  292. KOPP CR, Jandial A, Mishra K, Sandal R, et al
    Myasthenia gravis unmasked by imatinib.
    Br J Haematol. 2019;184:321.
    PubMed    


  293. WALLINGTON-BEDDOE CT, Xie V, Tong D, Powell JA, et al
    Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2019;184:443-447.
    PubMed    


  294. MINETTO P, Guolo F, Clavio M, Kunkl A, et al
    Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
    Br J Haematol. 2019;184:457-460.
    PubMed    


  295. BRANDER DM, Friedman DR, Volkheimer AD, Christensen DJ, et al
    SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
    Br J Haematol. 2019;184:605-615.
    PubMed     Abstract available


  296. GALEOTTI J, Coombs CC
    Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations.
    Br J Haematol. 2019;184:496.
    PubMed    


  297. KARUNAKARAN P, Yanamandra U, Nampoothiri RV, Khadwal A, et al
    Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia.
    Br J Haematol. 2019;184:672-673.
    PubMed    


  298. COLLORD G, Martincorena I, Young MD, Foroni L, et al
    Recurrent histone mutations in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2019;184:676-679.
    PubMed    


  299. OFRAN Y, Beohou E, Labopin M, Blaise D, et al
    Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey
    Br J Haematol. 2019;184:643-646.
    PubMed    


  300. FURNESS CL, Kirkwood A, Rowntree C, Vora A, et al
    Early morphological response is significantly associated with, but does not accurately predict, relapse in teenagers and young adults aged 10-24 years with acute lymphoblastic leukaemia (ALL): results from UKALL2003.
    Br J Haematol. 2019;184:663-666.
    PubMed    


  301. EYRE TA, Fox CP, Boden A, Bloor A, et al
    Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
    Br J Haematol. 2019;184:667-671.
    PubMed    


  302. PINTO AM, Papa FT, Frullanti E, Meloni I, et al
    Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia.
    Br J Haematol. 2019;184:657-659.
    PubMed    


    January 2019
  303. BATALLER A, Combalia A, Garcia-Herrera A, Estrach T, et al
    Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15744.
    PubMed    


  304. KHAKWANI M, Srinath S, Pratt G, Moss P, et al
    A rare complication of bone marrow aspiration and trephine biopsy: Staphylococcus aureus osteomyelitis and septicaemia.
    Br J Haematol. 2019;184:7.
    PubMed    


  305. HU AY, Zhou T
    Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.
    Br J Haematol. 2019;184:8.
    PubMed    


    November 2018
  306. BRIERLEY CK, Jones FM, Hanlon K, Peniket AJ, et al
    Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
    Br J Haematol. 2018 Nov 22. doi: 10.1111/bjh.15685.
    PubMed     Abstract available


    August 2018
  307. SU C, Bai HX, Xiao R
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some of the apparent ethnic dispa
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15526.
    PubMed    


  308. LO BELLO G, Naresh KN
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some apparent ethnic disparities.
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15527.
    PubMed    


    July 2018
  309. AILAWADHI S, Dholaria BR, Khurana S, Sher T, et al
    Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15458.
    PubMed    


    June 2018
  310. YEOH AE, Li Z, Dong D, Lu Y, et al
    Effective Response Metric: a novel tool to predict relapse in childhood acute lymphoblastic leukaemia using time-series gene expression profiling.
    Br J Haematol. 2018;181:653-663.
    PubMed     Abstract available


  311. MOZESSOHN L, Cheung MC, Fallahpour S, Gill T, et al
    Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
    Br J Haematol. 2018;181:803-815.
    PubMed     Abstract available


  312. ZHOU W, Goldin L, Wang M, McMaster ML, et al
    Combined somatic mutation and copy number analysis in the survival of familial CLL.
    Br J Haematol. 2018;181:604-613.
    PubMed     Abstract available


  313. CHIARETTI S, Messina M, Grammatico S, Piciocchi A, et al
    Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.
    Br J Haematol. 2018;181:642-652.
    PubMed     Abstract available


  314. BLAYNEY JK, Mills KI
    Compositional analysis gives insight into leukaemia cell lines expression profiles compared to those within patient sub-groups.
    Br J Haematol. 2018;181:847-851.
    PubMed    


  315. AW A, Hellman JM, Birner A, Davids MS, et al
    A complex case of ibrutinib treatment for a CLL patient on haemodialysis.
    Br J Haematol. 2018;181:854-857.
    PubMed    


  316. MCCLAIN CA, Bernhardt MB, Berger A, Bernini JC, et al
    Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
    Br J Haematol. 2018;181:684-687.
    PubMed    


  317. GHIONE P, Genuardi E, Rossi D, Drandi D, et al
    Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.
    Br J Haematol. 2018;181:693-695.
    PubMed    


  318. MEI H, Jiang H, Wu Y, Guo T, et al
    Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy.
    Br J Haematol. 2018;181:689-692.
    PubMed    


    May 2018
  319. SUTTON R
    Age matters in ALL.
    Br J Haematol. 2018;181:429-430.
    PubMed    


  320. SELLAR RS, Rowntree C, Vora AJ, Furness CL, et al
    Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003.
    Br J Haematol. 2018;181:515-522.
    PubMed     Abstract available


  321. SELLAR RS, Gale RE, Khwaja A, Garbowski M, et al
    Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome.
    Br J Haematol. 2018;181:486-494.
    PubMed     Abstract available


  322. KASPERS GJL, Niewerth D, Wilhelm BAJ, Scholte-van Houtem P, et al
    An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
    Br J Haematol. 2018;181:523-527.
    PubMed     Abstract available


  323. JIMENEZ JJ, DelCanto GM, Popovics P, Perez A, et al
    A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.
    Br J Haematol. 2018;181:476-485.
    PubMed     Abstract available


  324. LI S, Zhang J, Wang M, Fu G, et al
    Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Br J Haematol. 2018;181:360-371.
    PubMed     Abstract available


  325. PORPACZY E, Skrabs C, Schwarzinger I, Augustin D, et al
    Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib.
    Br J Haematol. 2018;181:431.
    PubMed    


  326. KURT H, Khoury JD, Medeiros LJ, Huh YO, et al
    Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations.
    Br J Haematol. 2018;181:305.
    PubMed    


  327. LOHSE S, Loew S, Kretschmer A, Jansen JHM, et al
    Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
    Br J Haematol. 2018;181:413-417.
    PubMed    


  328. MARTINEZ-LAPERCHE C, Kwon M, Franco-Villegas AC, Chillon MC, et al
    Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology.
    Br J Haematol. 2018;181:542-546.
    PubMed    


    April 2018
  329. FRIDTHJOF KS, Kampmann P, Dunweber A, Gorlov JS, et al
    Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15249.
    PubMed     Abstract available


  330. MALIK B, Taylor GP
    Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15234.
    PubMed    


  331. CITRIN R, Getz KD, Li Y, Huang YS, et al
    The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15159.
    PubMed    


  332. RIGOLIN GM, Saccenti E, Guardalben E, Cavallari M, et al
    In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.
    Br J Haematol. 2018;181:229-233.
    PubMed     Abstract available


  333. OSTGARD LSG, Norgaard M, Pedersen L, Ostgard RD, et al
    Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.
    Br J Haematol. 2018;181:205-214.
    PubMed     Abstract available


  334. CRASSINI KR, Zhang E, Balendran S, Freeman JA, et al
    Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.
    Br J Haematol. 2018;181:97-101.
    PubMed     Abstract available


  335. HOBO W, Hutten TJA, Schaap NPM, Dolstra H, et al
    Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.
    Br J Haematol. 2018;181:38-53.
    PubMed     Abstract available


  336. RASHIDI A, Weisdorf DJ, Bejanyan N
    Treatment of relapsed/refractory acute myeloid leukaemia in adults.
    Br J Haematol. 2018;181:27-37.
    PubMed     Abstract available


  337. SHRUBSOLE C, Collin M
    Tumour genesis syndrome in relapsed B lymphoblastic leukaemia.
    Br J Haematol. 2018;181:160.
    PubMed    


  338. DEMYANETS S, Jaeger E, Pablik E, Greiner G, et al
    The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia.
    Br J Haematol. 2018;181:137-139.
    PubMed    


  339. MATO AR, Timlin C, Ujjani C, Skarbnik A, et al
    Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
    Br J Haematol. 2018;181:259-261.
    PubMed    


  340. LIAO K, Zheng Z, Yang L, Wang L, et al
    Analysis of high-resolution human leucocyte antigen allele polymorphism in 3788 Han Chinese patients with leukaemia.
    Br J Haematol. 2018;181:278-281.
    PubMed    


  341. ARAI H, Nobusawa S, Kawabata-Iwakawa R, Rokudai S, et al
    Myeloid sarcoma arising in malignant phyllodes tumour: clonal relationships revealed by comparative genome-wide analyses.
    Br J Haematol. 2018;181:255-259.
    PubMed    


  342. MOLICA M, Breccia M, Colafigli G, Massaro F, et al
    Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
    Br J Haematol. 2018;181:275-278.
    PubMed    


  343. SORA F, Iurlo A, Sica S, Latagliata R, et al
    Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.
    Br J Haematol. 2018;181:267-270.
    PubMed    


  344. SOLER AM, Olano N, Mendez Y, Lopes A, et al
    TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay.
    Br J Haematol. 2018;181:252-255.
    PubMed    


  345. SCHULZ E, Lind K, Renner W, Petersen BS, et al
    The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls.
    Br J Haematol. 2018;181:148-151.
    PubMed    


    March 2018
  346. VAN TIENEN C, Visser O, Lugtenburg P, Taylor G, et al
    Overrepresentation of patients from HTLV-1 endemic countries among T cell Non-Hodgkin lymphomas in the Netherlands: an indication of under-diagnosis of Adult T cell leukaemia/lymphoma.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15160.
    PubMed    


  347. LOVISA F, Zecca M, Rossi B, Campeggio M, et al
    Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2018;180:680-693.
    PubMed     Abstract available


  348. GRIBBEN JG, Bosch F, Cymbalista F, Geisler CH, et al
    Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
    Br J Haematol. 2018;180:666-679.
    PubMed     Abstract available


  349. OHANIAN M, Pemmaraju N, Rozovski U, Alattar ML, et al
    Ocular extramedullary myeloid leukaemia.
    Br J Haematol. 2018;180:738-740.
    PubMed    


  350. STECKEL NK, Groth C, Mikesch JH, Trenschel R, et al
    High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2018;180:840-853.
    PubMed     Abstract available


  351. GUTIERREZ A, Kentsis A
    Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy.
    Br J Haematol. 2018;180:919-924.
    PubMed     Abstract available


  352. KONG Y, Song Y, Tang FF, Zhao HY, et al
    N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant.
    Br J Haematol. 2018;180:863-878.
    PubMed     Abstract available


  353. JURCZYSZYN A, Radocha J, Davila J, Fiala MA, et al
    Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
    Br J Haematol. 2018;180:831-839.
    PubMed     Abstract available


  354. GUZELKUCUK Z, Isik M, Ozcan AS, Demirkan TH, et al
    Imatinib-related interstitial lung disease.
    Br J Haematol. 2018;180:780.
    PubMed    


  355. DUTTA A, Yan D, Hutchison RE, Mohi G, et al
    STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice.
    Br J Haematol. 2018;180:911-915.
    PubMed    


  356. LANGE AP, Lima AS, Lucena-Araujo AR, Jacomo RH, et al
    The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.
    Br J Haematol. 2018;180:915-918.
    PubMed    


  357. GIONA F, Saglio G, Santopietro M, Menna G, et al
    Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.
    Br J Haematol. 2018;180:895-898.
    PubMed    


    February 2018
  358. ISHIDA T, Jo T, Takemoto S, Suzushima H, et al
    Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15123.
    PubMed    


  359. STOLZEL F
    From remission to cure: bypass or detour?
    Br J Haematol. 2018;180:317-318.
    PubMed    


  360. SUTTON R, Venn NC, Law T, Boer JM, et al
    A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
    Br J Haematol. 2018;180:550-562.
    PubMed     Abstract available


  361. KAYSER S, Levis MJ
    Advances in targeted therapy for acute myeloid leukaemia.
    Br J Haematol. 2018;180:484-500.
    PubMed     Abstract available


  362. HSU YT, Chen TY
    Relapsing polychondritis as a presenting feature of acute myeloid leukaemia.
    Br J Haematol. 2018;180:472.
    PubMed    


  363. ROUTLEDGE DJM, Tower C, Davies E, Scott M, et al
    Successful management of acute myeloid leukaemia in a twin pregnancy - a case report.
    Br J Haematol. 2018;180:605-606.
    PubMed    


  364. SIVINA M, Werner L, Rassenti L, Ferrajoli A, et al
    Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.
    Br J Haematol. 2018;180:597-600.
    PubMed    


  365. MAHDI AJ, Gosrani D, Chakraborty M, Rees A, et al
    Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
    Br J Haematol. 2018;180:603-604.
    PubMed    


  366. CONY-MAKHOUL P, Gardembas M, Coiteux V, Carpentier N, et al
    Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.
    Br J Haematol. 2018;180:356-364.
    PubMed     Abstract available


  367. DAVIES JK, Hassan S, Sarker SJ, Besley C, et al
    Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
    Br J Haematol. 2018;180:346-355.
    PubMed     Abstract available


  368. TANG FF, Xu LP, Zhang XH, Chen H, et al
    Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.
    Br J Haematol. 2018;180:448-451.
    PubMed    


    January 2018
  369. GOCKE CD, Gladstone DE
    The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    Br J Haematol. 2018;180:7-8.
    PubMed    


  370. KUHLEN M, Willasch AM, Dalle JH, Wachowiak J, et al
    Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
    Br J Haematol. 2018;180:82-89.
    PubMed     Abstract available


  371. ROGERS KA, Huang Y, Ruppert AS, Salem G, et al
    A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
    Br J Haematol. 2018;180:259-266.
    PubMed     Abstract available


  372. JAIN P, Nogueras Gonzalez GM, Kanagal-Shamanna R, Rozovski U, et al
    The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    Br J Haematol. 2018;180:33-40.
    PubMed     Abstract available


  373. REA D, Mahon FX
    How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
    Br J Haematol. 2018;180:24-32.
    PubMed     Abstract available


  374. ARUGA Y, Arakawa A, Ono K, Ogawa C, et al
    Pseudo-Chediak-Higashi granules and Auer rods in mixed phenotype acute leukaemia, T/myeloid, not otherwise specified.
    Br J Haematol. 2018;180:175.
    PubMed    


  375. WANG J, Morrissette J, Lieberman DB, Timlin C, et al
    Utilization of next generation sequencing identifies potentially actionable mutations in chronic lymphocytic leukaemia.
    Br J Haematol. 2018;180:299-301.
    PubMed    


  376. BENNETT CL, Berger JR, Sartor O, Carson KR, et al
    Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    Br J Haematol. 2018;180:301-304.
    PubMed    


  377. IBERRI DJ, Kwong BY, Stevens LA, Coutre SE, et al
    Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.
    Br J Haematol. 2018;180:164-166.
    PubMed    


  378. DIAMANTI P, Cox CV, Moppett JP, Blair A, et al
    Dual targeting of Hsp90 in childhood acute lymphoblastic leukaemia.
    Br J Haematol. 2018;180:147-149.
    PubMed    


    December 2017
  379. WOLACH O, Amitai I, DeAngelo DJ
    Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.
    Br J Haematol. 2017;179:705-723.
    PubMed     Abstract available


  380. PAVIGLIANITI A, Ruggeri A, Volt F, Sanz G, et al
    Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.
    Br J Haematol. 2017;179:790-801.
    PubMed     Abstract available


  381. KHARFAN-DABAJA MA, Al Malki MM, Deotare U, Raj RV, et al
    Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Br J Haematol. 2017;179:781-789.
    PubMed     Abstract available


  382. ITTEL A, Gervais C, Galoisy AC, M'Kacher R, et al
    Triradial and quadriradial chromosomes detected in a case of B-cell prolymphocytic leukaemia.
    Br J Haematol. 2017;179:704.
    PubMed    


  383. RAU RE, Carroll AJ, Heerema NA, Arland L, et al
    Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;179:843-846.
    PubMed    


    November 2017
  384. KOHNKE T, Wittmann VK, Bucklein VL, Lichtenegger F, et al
    Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.
    Br J Haematol. 2017;179:480-487.
    PubMed     Abstract available


  385. WU B, Slabicki M, Sellner L, Dietrich S, et al
    MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.
    Br J Haematol. 2017;179:421-429.
    PubMed     Abstract available


  386. CHEN Y, Cheng Y, Suo P, Yan C, et al
    Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantati
    Br J Haematol. 2017;179:598-605.
    PubMed     Abstract available


  387. IGWE IJ, Yang D, Merchant A, Merin N, et al
    The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis.
    Br J Haematol. 2017;179:618-626.
    PubMed     Abstract available


  388. DONADIEU J, Beaupain B, Fenneteau O, Bellanne-Chantelot C, et al
    Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history.
    Br J Haematol. 2017;179:557-574.
    PubMed     Abstract available


  389. MEDINGER M, Passweg JR
    Acute myeloid leukaemia genomics.
    Br J Haematol. 2017;179:530-542.
    PubMed     Abstract available


  390. BUSSI C, Iribarren P, Rodriguez CM
    Microtubule-associated protein 1A/1B-light chain 3 (LC3) 'decorates' intracytoplasmic inclusions in a patient with chronic lymphocytic leukaemia.
    Br J Haematol. 2017;179:529.
    PubMed    


  391. NAITHANI R
    Dasatinib-induced loss of eyebrows.
    Br J Haematol. 2017;179:362.
    PubMed    


  392. DUTTON D, Roach H, Lowry L
    Splenic rupture following temporary cessation of ibrutinib.
    Br J Haematol. 2017;179:361.
    PubMed    


  393. MUSGRAVE KM, van Delft FW, Avery PJ, Clack RM, et al
    Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.
    Br J Haematol. 2017;179:667-669.
    PubMed    


  394. GORDON MJ, Raess PW, Young K, Spurgeon SEF, et al
    Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
    Br J Haematol. 2017;179:501-503.
    PubMed    


  395. ABID MB, De Mel S
    Does ponatinib cross the blood-brain barrier?
    Br J Haematol. 2017;179:497-498.
    PubMed    


    October 2017
  396. HAN LJ, Wang Y, Fan ZP, Huang F, et al
    Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission.
    Br J Haematol. 2017;179:120-130.
    PubMed     Abstract available


  397. EWINS K, Malone A, Phelan E, Webb D, et al
    Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
    Br J Haematol. 2017;179:294-297.
    PubMed     Abstract available


  398. STELLRECHT CM, Chen LS, Ayres ML, Dennison JB, et al
    Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy.
    Br J Haematol. 2017;179:266-271.
    PubMed     Abstract available


  399. EDLINGER L, Berger-Becvar A, Menzl I, Hoermann G, et al
    Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.
    Br J Haematol. 2017;179:229-241.
    PubMed     Abstract available


  400. HUGHES TP, Munhoz E, Aurelio Salvino M, Ong TC, et al
    Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
    Br J Haematol. 2017;179:219-228.
    PubMed     Abstract available


  401. MO XD, Lv M, Huang XJ
    Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.
    Br J Haematol. 2017;179:184-197.
    PubMed     Abstract available


  402. MALONE A, Smith OP
    Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
    Br J Haematol. 2017;179:179-181.
    PubMed    


  403. YANAGISAWA R, Ogiso Y, Yoshikawa K, Tanaka M, et al
    Myelomonocytic differentiation associated with NPM1-RARA rearrangement.
    Br J Haematol. 2017;179:183.
    PubMed    


  404. SCHEFFOLD A, Jebaraj BMC, Jaramillo S, Tausch E, et al
    Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.
    Br J Haematol. 2017;179:342-346.
    PubMed    


    September 2017
  405. ALVAREZ-LARRAN A, Senin A, Fernandez-Rodriguez C, Pereira A, et al
    Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
    Br J Haematol. 2017;178:764-771.
    PubMed     Abstract available


  406. ZHANG X, Yang L, Liu X, Nie Z, et al
    Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
    Br J Haematol. 2017;178:728-738.
    PubMed     Abstract available


  407. FENAUX P, Muus P, Kantarjian H, Lyons RM, et al
    Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
    Br J Haematol. 2017;178:906-913.
    PubMed     Abstract available


  408. GOCKERITZ E, Vondey V, Guastafierro A, Pizevska M, et al
    Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    Br J Haematol. 2017;178:949-953.
    PubMed     Abstract available


  409. GHAMLOUCH H, Nguyen-Khac F, Bernard OA
    Chronic lymphocytic leukaemia genomics and the precision medicine era.
    Br J Haematol. 2017;178:852-870.
    PubMed     Abstract available


  410. KANTOROVA B, Malcikova J, Brazdilova K, Borsky M, et al
    Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.
    Br J Haematol. 2017;178:979-982.
    PubMed    


  411. VAN DER HELM LH, Berger G, Diepstra A, Huls G, et al
    Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.
    Br J Haematol. 2017;178:810-812.
    PubMed    


  412. TRACY I, Tapper W, Parker A, Gardiner A, et al
    Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.
    Br J Haematol. 2017;178:824-826.
    PubMed    


    August 2017
  413. DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
    Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
    PubMed     Abstract available


  414. ZWAAN CM, Kowalczyk J, Schmitt C, Bielorai B, et al
    Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14874.
    PubMed     Abstract available


  415. SCHETELIG J, de Wreede LC, Andersen NS, Moreno C, et al
    Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
    Br J Haematol. 2017;178:521-533.
    PubMed     Abstract available


  416. STRATI P, Parikh SA, Chaffee KG, Kay NE, et al
    Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
    Br J Haematol. 2017;178:394-402.
    PubMed     Abstract available


  417. ZELLER B, Glosli H, Forestier E, Ha SY, et al
    Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 x 109 /l. The NOPHO experience 1984-2014.
    Br J Haematol. 2017;178:448-456.
    PubMed     Abstract available


  418. KARLSSON L, Forestier E, Hasle H, Jahnukainen K, et al
    Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.
    Br J Haematol. 2017;178:592-602.
    PubMed     Abstract available


  419. MESSINA M, Chiaretti S, Fedullo AL, Piciocchi A, et al
    Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.
    Br J Haematol. 2017;178:583-587.
    PubMed     Abstract available


  420. EYRE TA, Schuh A
    An update for Richter syndrome - new directions and developments.
    Br J Haematol. 2017;178:508-520.
    PubMed     Abstract available


  421. SHVIDEL L
    Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
    Br J Haematol. 2017;178:347-348.
    PubMed    


  422. KWONG JHY, Leung RYY, Wong MLG, Gill H, et al
    Primary myelofibrosis presenting in acute promyelocytic transformation.
    Br J Haematol. 2017;178:349.
    PubMed    


  423. TAN RMR, Ganau M, Jeelani NUO, Tahir Z, et al
    Central nervous system aspergillosis resembling haemorrhagic brain infarct in a paediatric leukaemia patient.
    Br J Haematol. 2017;178:642-645.
    PubMed    


    July 2017
  424. CHEN Y, Pourabdollah M, Chang H
    Acute myeloid leukemia with mutated NPM1 demonstrating multilineage dysplasia and marked thrombocytosis.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14741.
    PubMed    


  425. THEUNISSEN PMJ, van den Branden A, Van Der Sluijs-Gelling A, De Haas V, et al
    Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2017;178:267-278.
    PubMed     Abstract available


  426. WILLIAMS J, Heppel NH, Britt-Compton B, Grimstead JW, et al
    Telomere length is an independent prognostic marker in MDS but not in de novo AML.
    Br J Haematol. 2017;178:240-249.
    PubMed     Abstract available


  427. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.
    Br J Haematol. 2017;178:106-111.
    PubMed     Abstract available


  428. MARTINI V, Gattazzo C, Frezzato F, Trimarco V, et al
    Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
    Br J Haematol. 2017;178:81-93.
    PubMed     Abstract available


  429. THEUNISSEN PMJ, Sedek L, De Haas V, Szczepanski T, et al
    Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Br J Haematol. 2017;178:257-266.
    PubMed     Abstract available


  430. SOARES M, Saussoy P, Maskens M, Reul H, et al
    Eliminating malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients.
    Br J Haematol. 2017;178:231-239.
    PubMed     Abstract available


  431. JONES JA, Hillmen P, Coutre S, Tam C, et al
    Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
    Br J Haematol. 2017;178:286-291.
    PubMed     Abstract available


  432. STRATI P, Parikh SA, Chaffee KG, Achenbach SJ, et al
    CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2017;178:99-105.
    PubMed     Abstract available


  433. TSUKAMOTO S, Kumazoe M, Huang Y, Lesnick C, et al
    SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells.
    Br J Haematol. 2017;178:155-158.
    PubMed    


    June 2017
  434. HO G, Jonas BA, Li Q, Brunson A, et al
    Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.
    Br J Haematol. 2017;177:791-799.
    PubMed     Abstract available


  435. ONIDA F, de Wreede LC, van Biezen A, Eikema DJ, et al
    Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Br J Haematol. 2017;177:759-765.
    PubMed     Abstract available


  436. LIU CY, Hsieh FS, Chu PY, Tsai WC, et al
    Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
    Br J Haematol. 2017;177:726-740.
    PubMed     Abstract available


  437. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
    Br J Haematol. 2017;177:1000-1007.
    PubMed     Abstract available


  438. CORREA DE ARAUJO KOURY L, Ganser A, Berliner N, Rego EM, et al
    Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.
    Br J Haematol. 2017;177:979-983.
    PubMed     Abstract available


  439. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal.
    Br J Haematol. 2017;177:991-999.
    PubMed     Abstract available


    May 2017
  440. TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
    PubMed     Abstract available


  441. EPPERLA N, Pham AQ, Burnette BL, Wiseman GA, et al
    Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14688.
    PubMed     Abstract available


  442. SCOTT S, Travis D, Whitby L, Bainbridge J, et al
    Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
    Br J Haematol. 2017;177:414-422.
    PubMed     Abstract available


  443. RHEINGOLD SR, Tasian SK, Whitlock JA, Teachey DT, et al
    A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
    Br J Haematol. 2017;177:467-474.
    PubMed     Abstract available


  444. THOMPSON PA, Stingo F, Keating MJ, Wierda WG, et al
    Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
    Br J Haematol. 2017;177:567-577.
    PubMed     Abstract available


  445. THOMPSON PA, Ravandi F
    How I manage patients with hairy cell leukaemia.
    Br J Haematol. 2017;177:543-556.
    PubMed     Abstract available


  446. NIBLOCK A, McConville DO, Morrison PJ
    Zygodactyly is strongly associated with Acute Myeloid Leukaemia.
    Br J Haematol. 2017;177:659-660.
    PubMed    


  447. EYRE TA, Fox CP, Shankara P, Went R, et al
    Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
    Br J Haematol. 2017;177:486-491.
    PubMed    


    April 2017
  448. MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
    Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
    PubMed     Abstract available


  449. TOKUNAGA M, Yonekura K, Nakamura D, Haraguchi K, et al
    Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14634.
    PubMed    


  450. BULDINI B, Rizzati F, Masetti R, Fagioli F, et al
    Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
    Br J Haematol. 2017;177:116-126.
    PubMed     Abstract available


  451. ORLOWSKI RJ, Porter DL, Frey NV
    The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
    Br J Haematol. 2017;177:13-26.
    PubMed     Abstract available


  452. AKAHANE K, Li Z, Etchin J, Berezovskaya A, et al
    Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;177:271-282.
    PubMed     Abstract available


  453. CURTIS DJ
    Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?
    Br J Haematol. 2017;177:169-170.
    PubMed    


  454. CHAN KL, Blombery P, Jones K, Lade S, et al
    Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.
    Br J Haematol. 2017;177:324-328.
    PubMed    


  455. FLEMING S, Ong DM, Jackson K, Avery S, et al
    Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.
    Br J Haematol. 2017;177:328-330.
    PubMed    


  456. DELGADO J, Bielig T, Bonet L, Carnero-Montoro E, et al
    Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens.
    Br J Haematol. 2017;177:147-150.
    PubMed    


    March 2017
  457. MINAMI M, Arita T, Iwasaki H, Muta T, et al
    Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14608.
    PubMed     Abstract available


  458. MARQUET J, Piris-Villaespesa M, Rodriguez E, Lopez S, et al
    Skin lesions and cytological features in HTLV-1 associated adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14600.
    PubMed    


  459. TASIAN SK, Hunger SP
    Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
    Br J Haematol. 2017;176:867-882.
    PubMed     Abstract available


  460. CHETTY T, Masingi NI, Laher Z, Pretorius E, et al
    Acute megakaryoblastic leukaemia: light microscopy and scanning electron microscopy of blast cells.
    Br J Haematol. 2017;176:686.
    PubMed    


  461. GROVE CS, Bolli N, Manes N, Varela I, et al
    Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution.
    Br J Haematol. 2017;176:825-829.
    PubMed    


  462. QUINQUENEL A, Sicre de Fontbrune F, Durot E, Pannetier M, et al
    Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
    Br J Haematol. 2017;176:997-999.
    PubMed    


  463. TAM CS, Kimber T, Seymour JF
    Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
    Br J Haematol. 2017;176:829-831.
    PubMed    


    February 2017
  464. SAWAS A, Farber CM, Schreeder MT, Khalil MY, et al
    A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
    Br J Haematol. 2017 Feb 21. doi: 10.1111/bjh.14534.
    PubMed     Abstract available


  465. SHARMAN JP, Farber CM, Mahadevan D, Schreeder MT, et al
    Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
    Br J Haematol. 2017;176:412-420.
    PubMed     Abstract available


  466. RINGDEN O, Labopin M, Schmid C, Sadeghi B, et al
    Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
    Br J Haematol. 2017;176:431-439.
    PubMed     Abstract available


  467. WAN H, Cai J, Chen F, Zhu J, et al
    SOX12: a novel potential target for acute myeloid leukaemia.
    Br J Haematol. 2017;176:421-430.
    PubMed     Abstract available


  468. BERTAINA A, Vinti L, Strocchio L, Gaspari S, et al
    The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Br J Haematol. 2017;176:629-636.
    PubMed     Abstract available


  469. VARGHESE AM, Howard DR, Pocock C, Rawstron AC, et al
    Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
    Br J Haematol. 2017;176:573-582.
    PubMed     Abstract available


  470. CHANG CK, Zhao YS, Xu F, Guo J, et al
    TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
    Br J Haematol. 2017;176:600-608.
    PubMed     Abstract available


  471. ROBAK T, Hellmann A, Kloczko J, Loscertales J, et al
    Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
    Br J Haematol. 2017;176:618-628.
    PubMed     Abstract available


  472. LUBBERT M, Ihorst G, Sander PN, Bogatyreva L, et al
    Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Br J Haematol. 2017;176:609-617.
    PubMed     Abstract available


  473. GAYNON PS
    "The Second Time is Sweeter After All".
    Br J Haematol. 2017;176:511-512.
    PubMed    


  474. BRANDER DM
    Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?
    Br J Haematol. 2017;176:337-340.
    PubMed    


  475. GUPTA A, Das A, Naina HV
    Cholecystitis as the initial presentation of acute myeloid leukaemia.
    Br J Haematol. 2017;176:344.
    PubMed    


  476. COELHO-SILVA JL, Carvalho LE, Oliveira MM, Franca-Neto PL, et al
    Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia.
    Br J Haematol. 2017;176:498-501.
    PubMed    


  477. BAI S, Hu S
    BCR-ABL1-negative acute myeloid leukaemia relapsing as BCR-ABL1-positive disease.
    Br J Haematol. 2017;176:514.
    PubMed    


    January 2017
  478. WANQUET A, Birsen R, Bonnet C, Boubaya M, et al
    Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    Br J Haematol. 2017;176:37-49.
    PubMed     Abstract available


  479. BROWN FC, Cifani P, Drill E, He J, et al
    Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
    Br J Haematol. 2017;176:86-91.
    PubMed     Abstract available


  480. SEKIYA Y, Xu Y, Muramatsu H, Okuno Y, et al
    Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;176:248-257.
    PubMed     Abstract available


  481. ZEIDAN AM, Smith BD, Carraway HE, Gojo I, et al
    A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
    Br J Haematol. 2017;176:241-247.
    PubMed     Abstract available


  482. HASLE H, Kaspers GJ
    Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.
    Br J Haematol. 2017;176:168-178.
    PubMed     Abstract available


  483. FRISHMAN-LEVY L, Izraeli S
    Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy.
    Br J Haematol. 2017;176:157-167.
    PubMed     Abstract available


  484. MAGEE JA
    Comment on: Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
    Br J Haematol. 2017;176:5-6.
    PubMed    


  485. PAN X, Nariai N, Fukuhara N, Saito S, et al
    Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
    Br J Haematol. 2017;176:318-321.
    PubMed    


    September 2016
  486. BIGENWALD C, Harel S, Chevignon F, Roos-Weil D, et al
    Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
    Br J Haematol. 2016 Sep 23. doi: 10.1111/bjh.14323.
    PubMed    


  487. BRAS AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, et al
    CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy.
    Br J Haematol. 2016 Sep 8. doi: 10.1111/bjh.14310.
    PubMed    


    June 2016
  488. GAYNON PS, Sun W
    Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:950-7.
    PubMed     Abstract available


  489. WILLIAMS ME, Hong F, Gascoyne RD, Wagner LI, et al
    Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Br J Haematol. 2016;173:867-75.
    PubMed     Abstract available


  490. GIONA F, Moleti ML, De Benedittis D, Santopietro M, et al
    Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.
    Br J Haematol. 2016;173:749-53.
    PubMed     Abstract available


  491. ZUNA J, Moericke A, Arens M, Koehler R, et al
    Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:742-8.
    PubMed     Abstract available


    May 2016
  492. TUCKER DL, Mihailescu L, Riordan R, Rule S, et al
    Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
    Br J Haematol. 2016 May 12. doi: 10.1111/bjh.14118.
    PubMed    


  493. SOVERINI S, De Benedittis C, Mancini M, Martinelli G, et al
    Present and future of molecular monitoring in chronic myeloid leukaemia.
    Br J Haematol. 2016;173:337-49.
    PubMed     Abstract available


  494. FERRET Y, Caillault A, Sebda S, Duez M, et al
    Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.
    Br J Haematol. 2016;173:413-20.
    PubMed     Abstract available


    March 2016
  495. TAKAHASHI H, Watanabe T, Kinoshita A, Yuza Y, et al
    High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.
    Br J Haematol. 2016 Mar 31. doi: 10.1111/bjh.14068.
    PubMed     Abstract available


  496. BURKHARDT B, Mueller S, Khanam T, Perkins SL, et al
    Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.
    Br J Haematol. 2016 Mar 15. doi: 10.1111/bjh.14017.
    PubMed     Abstract available


  497. MILES RR, Shah RK, Frazer JK
    Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2016 Mar 11. doi: 10.1111/bjh.14011.
    PubMed     Abstract available


    November 2015
  498. GIBSON SE, Leeman-Neill RJ, Jain S, Piao W, et al
    Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.
    Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13844.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: